• Explore /
  • Poster
  • / SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

Abstract Poster

Authors

null

Christoph Rochlitz

University Hospital, Basel, Switzerland

Christoph Rochlitz , Roger von Moos , Martin Bigler , Khalil Zaman , Sandro Anchisi , Marc Küng , Kyung Jae Na , Daniela Baertschi , Markus M. Borner , Tamara Rordorf , Daniel Rauch , Andreas Mueller , Thomas Ruhstaller , Marcus Vetter , Juerg Bernhard , Andreas Trojan , Ursula Hasler-Strub , Richard Cathomas , Ralph C. Winterhalder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01131195

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 518)

DOI

10.1200/jco.2014.32.15_suppl.518

Abstract #

518

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Mark P. Saunders

First Author: S. Hegewisch-Becker

First Author: Min Yan

First Author: Hideaki Bando